FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 10, 2026
Tenax Therapeutics, Inc. (TENX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $52.6 million.
Revenue (TTM)
$0
Net income (TTM)
$-64.86M
-106.0% vs year-ago TTM
Operating cash flow (TTM)
$-46.03M
-132.0% vs year-ago TTM
Free cash flow
$-11.39M
-4.9% vs prior year
EPS (TTM)
$-1.47
Dividend per share
None
Shares outstanding
17.20M
+333.1% vs prior year
Net cash
$1.94M
FY 2022
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TENX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chapel Hill, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 34956
- Former names
- OXYGEN BIOTHERAPEUTICS, INC. (until Sep 15, 2014); SYNTHETIC BLOOD INTERNATIONAL INC (until Jun 30, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Operating income | -$56.4M | -$19.5M | -$8.2M | $11.1M | -$32.7M |
| Net income | -$52.6M | -$17.6M | -$7.7M | $11.0M | -$32.5M |
| Diluted EPS | -$1.34 | -$1.15 | — | — | — |
| Operating cash flow | -$35.8M | -$14.8M | -$5.9M | -$11.4M | -$10.9M |
| Free cash flow | — | — | — | -$11.4M | -$10.9M |
| Total assets | $104.2M | $96.7M | $11.7M | $3.4M | $6.0M |
| Total liabilities | $7.2M | $4.7M | $3.6M | $1.9M | $1.7M |
| Stockholders' equity | $97.1M | $92.0M | $8.1M | $1.5M | $4.2M |
| Cash and investments | $97.6M | $94.9M | — | $2.1M | $5.6M |
| Total debt | — | — | $0 | $183,589 | $290,781 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 31, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Other events
|
Jul 2, 2026 | Jul 2, 2026 |
All 993 Tenax Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.